$1,318.00
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Chemotherapy
11 Corticosteroids
11 TKI therapy
11 Immunotherapy
12 Radiation therapy
12 Stem cell transplant
13 EPIDEMIOLOGY
16 MARKETED DRUGS
20 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Blincyto for ALL (December 10, 2019)
29 GC022 for ALL (December 7, 2019)
30 Blincyto for ALL (September 24, 2019)
32 KEY UPCOMING EVENTS
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 ADC Therapeutics In Asia JV, License Deal With Overland
35 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
41 BIBLIOGRAPHY
42 Prescription information
43 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of ALL, 2018–27
20 Figure 2: Overview of pipeline drugs for ALL in the US
20 Figure 3: Pipeline drugs for ALL, by company
21 Figure 4: Pipeline drugs for ALL, by drug type
21 Figure 5: Pipeline drugs for ALL, by classification
31 Figure 6: Blincyto for ALL (September 24, 2019): Phase III – Pediatric (1st Relapse)
32 Figure 7: Key upcoming events in ALL
33 Figure 8: Probability of success in the hematologic pipeline
37 Figure 9: Clinical trials in ALL
37 Figure 10: Top 10 drugs for clinical trials in ALL
38 Figure 11: Top 10 companies for clinical trials in ALL
38 Figure 12: Trial locations in ALL
39 Figure 13: ALL trials status
40 Figure 14: ALL trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of ALL, 2018–27
17 Table 2: Marketed drugs for ALL
22 Table 3: Pipeline drugs for ALL in the US
28 Table 4: Blincyto for ALL (December 10, 2019)
29 Table 5: GC022 for ALL (December 7, 2019)
30 Table 6: Blincyto for ALL (September 24, 2019)
35 Table 7: Historical global sales, by drug ($m), 2015–19
36 Table 8: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!